HIV/AIDS Clinical Trial
Official title:
iSTEP - an mHealth Physical Activity and Diet Intervention for Persons With HIV
NCT number | NCT03123731 |
Other study ID # | 161347 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | March 1, 2018 |
Est. completion date | May 31, 2023 |
Verified date | September 2023 |
Source | University of California, San Diego |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
HIV is associated with a pattern of neurocognitive deficits, metabolic dysfunction, and an elevated risk for cardiovascular disease (CVD), phenomena that remain untreated despite the use of medications to control the disease. This proposal will examine the effect of a personalized, automated, interactive mobile phone text message intervention (iSTEP) designed to increase moderate physical activity (PA), decrease sedentary behavior (SB), and promote a healthy Mediterranean-style diet (MedDiet) in persons living with HIV (PLWH). The investigators propose that participants who receive the iSTEP intervention will increase the amount of physical activity, improve their diet, show a reduction in risk factors for CVD, and exhibit improved neurocognitive performance.
Status | Completed |
Enrollment | 100 |
Est. completion date | May 31, 2023 |
Est. primary completion date | May 31, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - ability to provide informed consent - HIV infection documented at the University of California, San Diego (UCSD) HIV Neurobehavioral Research Program (HNRP) or assessed by an HIV test at screening - proficient in English - physically capable of participating in moderate PA as screened by the Physical Activity Readiness Questionnaire - consent from primary care physician to participate in the study - able to consume walnuts - no nut allergies Exclusion Criteria: - any physical conditions that would prevent moderate physical activity or where moderate physical activity would represent a health risk for the individual, including a history of myocardial infarction or stroke - unwillingness or inability to participate in daily text messaging - tree nut allergy that would prevent walnut consumption or other food restrictions that would prevent participation in the Mediterranean-style diet intervention (e.g., unable to eat fish or use olive oil for cooking). |
Country | Name | City | State |
---|---|---|---|
United States | HIV Neurobehavioral Research Program | San Diego | California |
Lead Sponsor | Collaborator |
---|---|
University of California, San Diego |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Physical activity - steps per day | Average number of daily steps recorded by the Fitbit | 6 months | |
Primary | Diet History Questionnaire (DHQ) | DHQ assessment of the percent of fat, carbohydrate, and protein intake in participant diet over the past month | Change from baseline to the 6-month visit after intervention | |
Secondary | Sedentary behavior - minutes per day | Average daily minutes of sedentary behavior (counts < 100/minute) quantified by GT3X Actigraph | Change from first week (Week 1) to last week (Week 24) of the intervention | |
Secondary | Fitness - 6-minute walk test (6MWT) | Time to complete 6-minute walk test around a 30 yard course; the score is the total yard distance completed. | Change from baseline to the 6-month visit after intervention | |
Secondary | Physical activity - moderate physical activity measured by actigraph | Average daily minutes of moderate physical activity quantified by GT3X Actigraph | Change from first week (Week 1) to last week (Week 24) of the intervention | |
Secondary | Physical activity - daily energy expenditure | Seven-day Physical Activity Recall - kilocalories per day | Change from first week (Week 1) to last week (Week 24) of the intervention | |
Secondary | Polyunsaturated fatty acids (PUFA) in plasma | One reported value of the total PUFA amount, consisting of the sum of a-linoleic acid (ALA), eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), and docosapentaenoic acid (DPA) levels in plasma. | Change from baseline to the 6-month visit after intervention | |
Secondary | Carotenoids in plasma | One reported value of the total carotenoid amount, consisting of the sum of alpha-carotene, beta-carotene, lutein, lycopene and betacryptoxanthin levels in plasma. | Change from baseline to the 6-month visit after intervention | |
Secondary | Interleukin-6 (IL6) | Levels of IL6 in plasma | Change from baseline to the 6-month visit after intervention | |
Secondary | C-reactive protein (CRP) | Levels of CRP in plasma | Change from baseline to the 6-month visit after intervention | |
Secondary | D-dimer | Levels of D-dimer in plasma | Change from baseline to the 6-month visit after intervention | |
Secondary | Tumor necrosis factor alpha (TNFa) | Levels of TNFa in plasma | Change from baseline to the 6-month visit after intervention | |
Secondary | Total cholesterol (TC) | Levels of TC in plasma | Change from baseline to the 6-month visit after intervention | |
Secondary | Low density lipoprotein cholesterol (LDL-C) | Levels of LDL-C in plasma | Change from baseline to the 6-month visit after intervention | |
Secondary | High density lipoprotein cholesterol (HDL-C) | Levels of HDL-C in plasma | Change from baseline to the 6-month visit after intervention | |
Secondary | Triglycerides | Levels of triglycerides in plasma | Change from baseline to the 6-month visit after intervention | |
Secondary | Wechsler Adult Intelligence Scale (WAIS) Digit Symbol | Neurocognitive assessment | Change from baseline to the 6-month visit after intervention | |
Secondary | WAIS Symbol Search | Neurocognitive assessment | Change from baseline to the 6-month visit after intervention | |
Secondary | Trail Making Test Part A | Neurocognitive assessment | Change from baseline to the 6-month visit after intervention | |
Secondary | Trail Making Test Part B | Neurocognitive assessment | Change from baseline to the 6-month visit after intervention | |
Secondary | Hopkins Verbal Learning Test - Revised | Neurocognitive assessment | Change from baseline to the 6-month visit after intervention | |
Secondary | Brief Visuospatial Memory Test - Revised | Neurocognitive assessment | Change from baseline to the 6-month visit after intervention | |
Secondary | Wisconsin Card Sorting Test | Neurocognitive assessment | Change from baseline to the 6-month visit after intervention | |
Secondary | Controlled Oral Word Association Test | Neurocognitive assessment | Change from baseline to the 6-month visit after intervention | |
Secondary | Category Fluency | Neurocognitive assessment | Change from baseline to the 6-month visit after intervention | |
Secondary | WAIS Letter-Number Sequencing | Neurocognitive assessment | Change from baseline to the 6-month visit after intervention | |
Secondary | Paced Auditory Serial Addition Task | Neurocognitive assessment | Change from baseline to the 6-month visit after intervention | |
Secondary | Grooved Pegboard Test. | Neurocognitive assessment | Change from baseline to the 6-month visit after intervention |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03413696 -
Effects of Health Literacy and HCV Knowledge on HCV Treatment Willingness in HIV-coinfected Patients
|
||
Completed |
NCT03289676 -
Storytelling Narrative Communication Intervention for Smoking Cessation in Women Living With HIV
|
Phase 1 | |
Completed |
NCT03215901 -
Life Plans Intervention Study
|
N/A | |
Completed |
NCT03268551 -
MEMO-Medical Marijuana and Opioids Study
|
||
Active, not recruiting |
NCT04064567 -
Linking High-Risk Jail Detainees to HIV Pre-Exposure Prophylaxis: PrEP-LINK
|
N/A | |
Completed |
NCT04013295 -
Prize-linked Savings Initiatives for Promoting Better Health and Economic Outcomes in Kenya
|
N/A | |
Recruiting |
NCT04405700 -
Measuring Adverse Pregnancy and Newborn Congenital Outcomes
|
||
Recruiting |
NCT03984136 -
HIV Results Exchange Mechanism on Promoting HIV Testing Among MSM
|
N/A | |
Completed |
NCT02928900 -
Patient Actor Training to Improve HIV Services for Adolescents in Kenya
|
N/A | |
Recruiting |
NCT03268109 -
COGnitive ImpairmenT in Older HIV-infected Patients ≥ 65 Years Old
|
||
Completed |
NCT02797262 -
Measuring and Monitoring Adherence to ART With Pill Ingestible Sensor System
|
N/A | |
Completed |
NCT02376582 -
Safety and Immunogenicity Study of a DNA Vaccine Combined With Protein Vaccine Against HIV/AIDS
|
Phase 1 | |
Completed |
NCT01957865 -
Real-Time Antiretroviral Therapy Adherence Intervention in Uganda
|
N/A | |
Terminated |
NCT01443923 -
Boceprevir Drug Combination for Hepatitis C Treatment in People With and Without HIV
|
Phase 4 | |
Completed |
NCT01616940 -
Minority AIDS Initiative Retention and Re-Engagement Project
|
N/A | |
Completed |
NCT01910714 -
Adapting and Evaluating an EBI to Prevent HIV/AIDS Risk Among Apache Youth
|
N/A | |
Completed |
NCT01084421 -
A Computer-Based Parent/Adolescent HIV Communication Intervention for Latinos
|
N/A | |
Completed |
NCT01596322 -
International HIV Antiretroviral Adherence, Resistance and Survival
|
N/A | |
Completed |
NCT03643705 -
A Nurse-led Intervention to Extend the HIV Treatment Cascade for Cardiovascular Disease Prevention
|
N/A | |
Completed |
NCT03923231 -
Pharmacokinetics of Atazanavir in Special Populations
|